PureTech wins FDA Fast Track status for LYT-200 in relapsed or refractory high-risk MDS

• PureTech won FDA Fast Track designation for LYT-200 with a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
• FDA End-of-Phase 1 meeting backed moving LYT-200 into the Phase 2 STRIDE-MDS trial, a randomized, double-blind, placebo-controlled study.
• Phase 2 plans call for about 125 patients, testing two LYT-200 doses to support dose selection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PureTech Health plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202609210200BIZWIRE_USPR_____20260920_BW743286) on September 21, 2026, and is solely responsible for the information contained therein.